Covington & Burling advised AbbVie on the transaction, and Fenwick & West advised Aliada Therapeutics. AbbVie (NYSE: ABBV), a pharmaceutical firm, announced it has entered into...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Morphic Holdings, Inc. in the transaction, and Kirkland & Ellis represented Eli Lilly and Company. Eli Lilly and Company (NYSE: LLY) announced...
You must be a Standard 1 Year member to access this content.
Fenwick & West is advising Escient Pharmaceuticals on the transaction, and Covington & Burling is advising Incyte. Incyte (Nasdaq:INCY) announced the acquisition of Escient Pharmaceuticals (“Escient”). Incyte...
You must be a Standard 1 Year member to access this content.
Fenwick & West advised Stoke Therapeutics on the offering, Wilson Sonsini Goodrich & Rosati advised Stoke on IP matters and Davis Polk & Wardwell advised the...
You must be a Standard 1 Year member to access this content.
Skadden advised Vertex Pharmaceuticals Incorporated, while Fenwick & West advised Alpine in the transaction. Vertex Pharmaceuticals Incorporated and Alpine Immune Sciences, Inc. have entered into a definitive...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Samsara BioCapital in the transaction. Alumis Inc. announced an upsized $259M Series C financing round co-led by existing investor, Foresite Capital, and new...
You must be a Standard 1 Year member to access this content.
Fenwick & West LLP represented Chinook Therapeutics, Inc. on the transaction, while Hogan Lovells US LLP represented Novartis AG. Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company, announced...
You must be a Standard 1 Year member to access this content.
Fenwick represented Morphic Holding, Inc. on the deal. Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment...
You must be a Standard 1 Year member to access this content.
Fenwick represented Abdera Therapeutics on the deal. Abdera Therapeutics, a biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable, precision radiopharmaceuticals...
You must be a Standard 1 Year member to access this content.
Fenwick represented Third Harmonic Bio, Inc. on the deal. Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT...
You must be a Standard 1 Year member to access this content.
Fenwick & West advised Amunix on the deal, while Weil, Gotshal & Manges advised Sanofi. Amunix, an immuno-oncology company, announced its pending acquisition by Sanofi, a global...
You must be a Standard 1 Year member to access this content.
Fenwick & West advised Vanqua Bio on the deal. Vanqua Bio, a biopharmaceutical company dedicated to discovering and developing next-generation medicines for neurodegenerative diseases, announced its $85...
You must be a Standard 1 Year member to access this content.
